Adagene (ADAG) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Adagene (ADAG) has outperformed Sionna Therapeutics (SION) over the past year, losing 2.2% versus a loss of 93.5%. Sionna Therapeutics is the larger company by market cap ($127.8 million vs $118.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | SION |
|---|---|---|
| Share price | $1.76 | $2.83 |
| Market cap | $118.17M | $127.79M |
| 1-day change | -12.44% | -4.88% |
| YTD return | -6.88% | -93.13% |
| 1-year return | -2.22% | -93.53% |
| 5-year return | -79.75% | — |
| EPS (TTM) | $-0.37 | $-2.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.67M | — |
| Revenue growth (YoY) | +7332.76% | — |
| Net income (latest FY) | $-17.61M | $-75.27M |
| Operating margin | -279.48% | — |
| Net margin | -229.56% | — |
| 52-week high | $4.85 | $54.97 |
| 52-week low | $1.27 | $2.75 |
| Distance from 52-week high | -63.71% | -94.86% |
| Analyst consensus | none | hold |
| Avg. price target upside | +463.07% | +643.36% |
| Average volume | 348.81K | 1.12M |
| Shares outstanding | 67.14M | 45.24M |
| Employees | 128 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed SION by 91.3 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
ADAG vs SION FAQ
Which is bigger, Adagene or Sionna Therapeutics?
Sionna Therapeutics (SION) is larger, with a market capitalization of $127.79M compared with $118.17M for Adagene (ADAG).
Which stock has performed better over the past year, ADAG or SION?
ADAG returned -2.22% over the past 12 months, compared with -93.53% for SION (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Sionna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.